McGill University today announced it has signed agreements with ModernaTX, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to support two innovative research projects in the area of lipid nanoparticles (LNPs). LNPs are critical components in mRNA medicines such as vaccines, as they are the primary delivery method of mRNA strands to the target cells.
Read MoreUnder the agreement, Defence will develop the first radio-immuno-conjugate therapy based on an Auger electron emitter by combining Defence’s intracellular targeting and radiochemistry expertise provided by Orano SA, a world-renowned multinational company based in Chatillon, France.
Read MoreAstraZeneca is pleased to announce it is bringing 500 highly-skilled scientific and high-tech jobs to the Greater Toronto Area (GTA) in a major expansion of its research footprint in Canada. The investment will contribute to AstraZeneca’s Research & Development Hub (R&D) in Mississauga, which focuses on leading global clinical studies in areas including breast, lung and prostate cancer, COVID-19, and chronic kidney disease. It also includes the creation of a new Alexion, AstraZeneca Rare Disease Development Hub, which focuses on rare disease research.
Read MoreToday, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, and the Honourable Jean-Yves Duclos, Minister of Health, announced an investment of $10 million in support of the creation of five research hubs to accelerate Canada’s vaccine and therapeutics production.
Read MoreCongruence Therapeutics, announced today the close of an extension to its Series A financing, bringing the total amount raised to over US$65 million. This extension was led by new investor BDC Capital's Thrive Venture Fund, with participation from current investors Amplitude Ventures, Fonds de solidarité FTQ, OrbiMed, Investissement Quebec (IQ), SilverArc, and others.
Read MoreAlthough Fragment-Based Lead Discovery (FBLD) is one of the most promising strategies for discovering future medical compounds, there are still until today barriers that discourage industry from pursuing this approach.
Read MoreLaurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing LAU-7b (oral fenretinide) as a first-in-class inflammation-controlling drug candidate for Cystic Fibrosis (CF), announces the presentation of results from its placebo-controlled Phase 2 APPLAUD 24-week clinical study in adults with CF at the North American Cystic Fibrosis Conference (NACFC) currently held in Philadelphia, United States.
Read MoreInnovative Medicines Canada’s (IMC) initial interpretation of the Patented Medicine Prices Review Board’s (PMPRB) revised draft Guidelines is that they will further reduce the availability of new medicines in Canada by exacerbating an already unpredictable regulatory environment.
Read MoreThe Canadian Cancer Society (CCS), CQDM, the Cole Foundation and Oncopole – pôle cancer du FRQS announced, today, grants of $8,485,132 to finance four research projects in Quebec, as part of the Pediatric Cancer Research Initiative.
Read MoreECOGENE-21, a non-profit clinical and academic research organisation dedicated to providing access to innovation for unmet health needs, including rare or severe diseases, successfully completed the first flight demonstrations of the drone delivery process for clinical trials at the Centre of Excellence on Drones (CED) in Alma on September 28.
Read MoreTheratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of SORT1, the target for Theratechnologies’ oncology platform, in several cancer types.
Read MoreGénome Québec is happy to announce today the eleven research teams, from four Québec universities, that have received major funding in genomics. The total investment, including that of public and private partners, amounts to more than $4 million as part of the first round of the Genomics integration program – Human health.
Read MoreadMare BioInnovations (adMare) and Medicine by Design are pleased to announce their new memorandum of understanding (MOU) to support translation priorities, which will accelerate health innovation commercialization in the Toronto life sciences ecosystem and in Canada.
Read MoreInversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the completion of a Series C funding of $95 million CAD (approximately $70 million USD), led by New Enterprise Associates (“NEA”).
Read MoreMONTRÉAL, June 17, 2022 – ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that it has submitted a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for UM171, a proprietary molecule being studied for use in the expansion and rejuvenation of hematopoietic stem cells.
Read MoreBIOQuébec is proud to be organizing, in partnership with Investissement Québec International, the Quebec CROs mission during MassBio’s State of Possible Conference, being held from May 4 to 6.
Read MoreBROMONT, Québec--(BUSINESS WIRE)--BIOQuébec welcomes the tabling of the 2022-2025 Quebec Life Sciences Strategy (QLSS) which will support - and above all, foster - the growth of Quebec’s life sciences ecosystem. The second version of the QLSS features three major objectives, five areas of focus, and ten promising measures for the industry.
Read MoreGE Healthcare will incorporate Imeka's neuroimaging technology into BrainWave MRI to provide additional insights into central nervous system diseases and disorders
Read MoreOn behalf of the member companies of the biotechnology and life sciences organizations across Canada, we are writing on this occasion to urge the government to oppose the TRIPS waivers proposal before the World Trade Organization which would allow countries to force the transfer of intellectual property and know-how on covid-19 vaccines. The proposed waiver fundamentally undermines the very system that produced the current group of COVID-19 vaccines and will be a disincentive for the investors and companies taking risks to develop solutions for the next health emergency.
Read MoreThe COVID-19 pandemic has underlined the essential role of the biotechnology sector. Québec has a wealth of talented researchers and entrepreneurs in several specialties, including neurology, oncology, rare diseases and cardiology. And investors in the province believe that the life sciences will play a major economic role in the post-coronavirus era.
Read More
